Send a note to Doug Wintemute, Kara Coleman Fields and our other editors. We read every email. By submitting this form, you agree to allow us to collect, store, and potentially publish your provided ...

FDA accepted Replimune’s resubmitted Biologics License Application for RP1 combined with Bristol Myers Squibb’s Opdivo to treat advanced melanoma The agency set April 10, 2026 as the decision deadline ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

Hello Pythonistas, if you have started from here, you might not yet understand Python programs. For this, you need to understand the Python syntax. It’s like the grammar of Python. After reading this, ...

Getting input from users is one of the first skills every Python programmer learns. Whether you’re building a console app, validating numeric data, or collecting values in a GUI, Python’s input() ...

Functions are the building blocks of Python programming. They let you organize your code, reduce repetition, and make your programs more readable and reusable. Whether you’re writing small scripts or ...

Shares of Replimune (NASDAQ:REPL) plunged ~38% in the premarket on Monday after Stat News reported that the FDA’s top regulator of cancer drugs intervened during the review of the company’s lead asset ...

Despite a sharp drop in the previous session following the FDA rejection of its skin cancer drug RP1, Replimune (NASDAQ:REPL) shares bounced back on Wednesday even as multiple Wall Street analysts ...

Replimune Group, Inc. (NASDAQ:REPL) stock plunged on Tuesday after a U.S. Food and Drug Administration (FDA) update. The clinical stage biotechnology company received an FDA Complete Response Letter ...

A self-hosting Python REPL with Gemini AI integration, featuring conversation context, tool use, and logging. $ gmake repl ╔══════════════════════════════════════╗ ║ 🌟 Gemini REPL v0.1.0 🌟 ║ ║ ...

Multiple analysts have issued price targets for $REPL recently. We have seen 4 analysts offer price targets for $REPL in the last 6 months, with a median target of ...